These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17686472)

  • 1. Intraparenchymal injections of acid sphingomyelinase results in regional correction of lysosomal storage pathology in the Niemann-Pick A mouse.
    Yang WW; Dodge JC; Passini MA; Taksir TV; Griffiths D; Schuchman EH; Cheng SH; Shihabuddin LS
    Exp Neurol; 2007 Oct; 207(2):258-66. PubMed ID: 17686472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease.
    Dodge JC; Clarke J; Treleaven CM; Taksir TV; Griffiths DA; Yang W; Fidler JA; Passini MA; Karey KP; Schuchman EH; Cheng SH; Shihabuddin LS
    Exp Neurol; 2009 Feb; 215(2):349-57. PubMed ID: 19059399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease.
    Passini MA; Macauley SL; Huff MR; Taksir TV; Bu J; Wu IH; Piepenhagen PA; Dodge JC; Shihabuddin LS; O'Riordan CR; Schuchman EH; Stewart GR
    Mol Ther; 2005 May; 11(5):754-62. PubMed ID: 15851014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropathology of the acid sphingomyelinase knockout mouse model of Niemann-Pick A disease including structure-function studies associated with cerebellar Purkinje cell degeneration.
    Macauley SL; Sidman RL; Schuchman EH; Taksir T; Stewart GR
    Exp Neurol; 2008 Dec; 214(2):181-92. PubMed ID: 18778708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injection of mouse and human neural stem cells into neonatal Niemann-Pick A model mice.
    Sidman RL; Li J; Stewart GR; Clarke J; Yang W; Snyder EY; Shihabuddin LS
    Brain Res; 2007 Apr; 1140():195-204. PubMed ID: 17289003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infusion of recombinant human acid sphingomyelinase into niemann-pick disease mice leads to visceral, but not neurological, correction of the pathophysiology.
    Miranda SR; He X; Simonaro CM; Gatt S; Dagan A; Desnick RJ; Schuchman EH
    FASEB J; 2000 Oct; 14(13):1988-95. PubMed ID: 11023983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann-Pick disease.
    Miranda SR; Erlich S; Friedrich VL; Gatt S; Schuchman EH
    Gene Ther; 2000 Oct; 7(20):1768-76. PubMed ID: 11083499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-Pick-A mouse leads to a marked decrease in lysosomal storage pathology.
    Shihabuddin LS; Numan S; Huff MR; Dodge JC; Clarke J; Macauley SL; Yang W; Taksir TV; Parsons G; Passini MA; Gage FH; Stewart GR
    J Neurosci; 2004 Nov; 24(47):10642-51. PubMed ID: 15564580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease.
    Barbon CM; Ziegler RJ; Li C; Armentano D; Cherry M; Desnick RJ; Schuchman EH; Cheng SH
    Mol Ther; 2005 Sep; 12(3):431-40. PubMed ID: 16099409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel biomarkers for Niemann-Pick disease using gene expression analysis of acid sphingomyelinase knockout mice.
    Dhami R; Passini MA; Schuchman EH
    Mol Ther; 2006 Mar; 13(3):556-64. PubMed ID: 16214420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency:the utility of animal models of disease in the toxicological evaluation of potential therapeutics.
    Murray JM; Thompson AM; Vitsky A; Hawes M; Chuang WL; Pacheco J; Wilson S; McPherson JM; Thurberg BL; Karey KP; Andrews L
    Mol Genet Metab; 2015 Feb; 114(2):217-25. PubMed ID: 25092414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary delivery of recombinant acid sphingomyelinase improves clearance of lysosomal sphingomyelin from the lungs of a murine model of Niemann-Pick disease.
    Ziegler RJ; Brown C; Barbon CM; D'Angona AM; Schuchman EH; Andrews L; Thurberg BL; McPherson JM; Karey KP; Cheng SH
    Mol Genet Metab; 2009 May; 97(1):35-42. PubMed ID: 19231265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease.
    Dodge JC; Clarke J; Song A; Bu J; Yang W; Taksir TV; Griffiths D; Zhao MA; Schuchman EH; Cheng SH; O'Riordan CR; Shihabuddin LS; Passini MA; Stewart GR
    Proc Natl Acad Sci U S A; 2005 Dec; 102(49):17822-7. PubMed ID: 16301517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adeno-associated viral vector serotype 9-based gene therapy for Niemann-Pick disease type A.
    Samaranch L; Pérez-Cañamás A; Soto-Huelin B; Sudhakar V; Jurado-Arjona J; Hadaczek P; Ávila J; Bringas JR; Casas J; Chen H; He X; Schuchman EH; Cheng SH; Forsayeth J; Bankiewicz KS; Ledesma MD
    Sci Transl Med; 2019 Aug; 11(506):. PubMed ID: 31434754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A.
    Bu J; Ashe KM; Bringas J; Marshall J; Dodge JC; Cabrera-Salazar MA; Forsayeth J; Schuchman EH; Bankiewicz KS; Cheng SH; Shihabuddin LS; Passini MA
    Mol Ther; 2012 Oct; 20(10):1893-901. PubMed ID: 22828503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse.
    Passini MA; Bu J; Fidler JA; Ziegler RJ; Foley JW; Dodge JC; Yang WW; Clarke J; Taksir TV; Griffiths DA; Zhao MA; O'Riordan CR; Schuchman EH; Shihabuddin LS; Cheng SH
    Proc Natl Acad Sci U S A; 2007 May; 104(22):9505-10. PubMed ID: 17517638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of myelin-specific proteins and sphingolipids characterize the brains of acid sphingomyelinase-deficient mice, an animal model of Niemann-Pick disease type A.
    Buccinnà B; Piccinini M; Prinetti A; Scandroglio F; Prioni S; Valsecchi M; Votta B; Grifoni S; Lupino E; Ramondetti C; Schuchman EH; Giordana MT; Sonnino S; Rinaudo MT
    J Neurochem; 2009 Apr; 109(1):105-15. PubMed ID: 19187445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease.
    Horinouchi K; Erlich S; Perl DP; Ferlinz K; Bisgaier CL; Sandhoff K; Desnick RJ; Stewart CL; Schuchman EH
    Nat Genet; 1995 Jul; 10(3):288-93. PubMed ID: 7670466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-induced lysosomal damage after demyelination corrupts microglia protective function in lysosomal storage disorders.
    Gabandé-Rodríguez E; Pérez-Cañamás A; Soto-Huelin B; Mitroi DN; Sánchez-Redondo S; Martínez-Sáez E; Venero C; Peinado H; Ledesma MD
    EMBO J; 2019 Jan; 38(2):. PubMed ID: 30530526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingomyelin 16:0 is a therapeutic target for neuronal death in acid sphingomyelinase deficiency.
    Gaudioso Á; Jiang X; Casas J; Schuchman EH; Ledesma MD
    Cell Death Dis; 2023 Apr; 14(4):248. PubMed ID: 37024473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.